Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia

NACompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Type 1 Diabetes
Interventions
DRUG

Apidra

Subjects on this treatment arm will receive Apidra insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.

DRUG

Humalog

Subjects on this treatment arm will receive Humalog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.

DRUG

Novolog

Subjects on this treatment arm will receive Novolog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians. (NOTE: This arm was only for one year of the study which was the 2012 camp session.)

Trial Locations (1)

32130

Camp Winona, DeLeon Springs

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

University of Florida

OTHER